These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981 [TBL] [Abstract][Full Text] [Related]
28. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072 [TBL] [Abstract][Full Text] [Related]
29. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159 [TBL] [Abstract][Full Text] [Related]
30. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621 [TBL] [Abstract][Full Text] [Related]
31. Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. van den Heuvel L; Lim AS; Visanji NP; Huang J; Ghate T; Mestre TA; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Pondal M; Faust-Socher A; Rogaeva E; Tomlinson G; Lang AE; Marras C J Parkinsons Dis; 2018; 8(1):131-139. PubMed ID: 29480219 [TBL] [Abstract][Full Text] [Related]
32. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514 [TBL] [Abstract][Full Text] [Related]
33. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review. Peng F; Sun YM; Chen C; Luo SS; Li DK; Wang YX; Yang K; Liu FT; Zuo CT; Ding ZT; An Y; Wu JJ; Wang J J Neurol Sci; 2017 Feb; 373():23-26. PubMed ID: 28131193 [TBL] [Abstract][Full Text] [Related]
34. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868 [TBL] [Abstract][Full Text] [Related]
35. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N; Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001 [TBL] [Abstract][Full Text] [Related]